PDF herunterladen
Handchir Mikrochir Plast Chir 2010; 42(1): 19-29
DOI: 10.1055/s-0030-1247501
Übersichtsarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Medikamentöse Behandlung des CRPS

Drug Treatment of CRPSS. Rüegg1
  • 1Universitätsspital Basel, Neurologie, Basel, Schweiz
Weitere Informationen

Publikationsverlauf

eingereicht 25.9.2009

akzeptiert 6.1.2010

Publikationsdatum:
04. März 2010 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Das komplexe regionale Schmerzsyndrom (CRPS) ist gekennzeichnet durch einen charakteristischen stadienhaften Ablauf mit den Hauptsymptomen Schmerzen, trophischen und entzündlichen Veränderungen sowie Funktionseinschränkung bis -verlust. Während das letzte mit intensiver Physio- und Ergotherapie behandelt werden muss, können die ersten drei Symptome medikamentös beeinflusst werden: Hauptpfeiler der medikamentösen Therapie der neuropathischen Schmerzen sind Antidepressiva, Antiepileptika und Opioide, während die eigentlichen akuten nozizeptiven Schmerzen und die akute Entzündung auf nicht-steroidale Analgetika und Steroide ansprechen. Zusätzlich wirken auch Calcitonin und die Osteoklasten hemmenden Biphosphonate schmerzlindernd und knochenerhaltend. Der Einsatz von Sympathikolytika außerhalb von lokoregionalen Anästhesieverfahren (welche an anderer Stelle besprochen werden) ist umstritten. Allgemein gibt es im Gebiet der medikamentösen Schmerzbehandlung spezifisch des komplexen regionalen Schmerzsyndroms nur sehr geringe Evidenz; die meisten Erkenntnisse werden aus der Behandlung anderer chronischer neuropathischer Schmerzsyndrome (wie diabetische Polyneuropathie oder post-Zoster-Schmerzen) übernommen oder beruhen auf pathophysiologischen Überlegungen.

Abstract

The main symptoms of excruciating pain, trophic and inflammatory changes, as well as functional impairment of limbs are the hallmark of the complex regional pain syndrome (CRPS). While functional impairments have to be treated by physical and occupational therapy, the former three symptoms are amendable to drug treatment: antidepressants, antiepileptic drugs and opioids are the most important drug classes for alleviating neuropathic pain whereas acute nociceptive pain may be positively influenced by non-steroidal anti-inflammatory drugs and steroids. In addition, calcitonin and the biphosphonates inhibit osteoclasts and therefore loss of bone mass and may thus also reduce pain. The use of sympatholytic agents beyond locoregional anesthesia techniques (which are covered elsewhere in this issue) is not unequivocal. In general, the evidence level for treatment strategies specifically for the complex regional pain syndrome is very poor; most recommendations and algorithms rely on results derived from studies testing drugs against other conditions where chronic (neuropathic) pain is prevalent, like diabetic polyneuropathy or postherpetic neuralgia, or medications are used on the basis of pathomechanistic considerations.

Schlüsselwörter

komplexes regionales Schmerzsyndrom (CRPS) - neuropathisch - Behandlung - Antidepressiva - Opiate

Key words

complex regional pain syndrome (CRPS) - neuropathic - treatment - antidepressants - opioids

Literatur

  • 1 Pappagallo M, Rosenberg AD. Epidemiology, pathophysiology, and management of complex regional pain syndrome.  Pain Pract. 2001;  1 11-20
    Google Scholar
  • 2 Beniczky S, Tajti J, Timea Varga E. et al . Evidence-based pharmacological treatment of neuropathic pain syndromes.  J Neural Trans. 2005;  112 735-749
    Google Scholar
  • 3 Littlejohn G. Regional pain syndrome: clinical characteristics, mechanisms and management.  Nat Clin Pract Rheumatol. 2007;  3 504-511
    Google Scholar
  • 4 Stanton-Hicks MD, Burton WA, Bruehl SP. et al . An updated interdisciplinary clinical pathway for CRPS: Report of an expert panel.  Pain Pract. 2002;  2 1-16
    Google Scholar
  • 5 Burton AW, Hassenbusch III SJ, Warneke C. et al . Complex regional pain syndrome (CRPS): Survey of current practices.  Pain Pract. 2004;  4 74-83
    Google Scholar
  • 6 Birklein F. Complex regional pain syndrome.  J Neurol. 2005;  252 131-138
    Google Scholar
  • 7 Li Z, Paterson Smith B, Smith TL. et al . Diagnosis and management of complex regional pain syndrome complicating upper extremity recovery.  J Hand Ther. 2005;  18 270-276
    Google Scholar
  • 8 Berthelot JM. Current management of reflex sympathetic dystrophy syndrome (complex regional pain syndrome type I).  Joint Bone Spine. 2006;  73 495-499
    Google Scholar
  • 9 Rowbotham MC. Pharmacologic management of complex regional pain syndrome.  Clin J Pain. 2006;  22 425-429
    Google Scholar
  • 10 Mackey S, Feinberg S. Pharmacologic therapies for complex regional pain syndrome.  Curr Pain Headache Rep. 2007;  11 38-43
    Google Scholar
  • 11 Eisenberg E, Geller R, Brill S. Pharmacotherapy options for complex regional pain syndrome.  Expert Rev Neurotherapeutics. 2007;  7 521-531
    Google Scholar
  • 12 Albazaz R, Wong YT, Homer-Vanniasinkam S. Complex regional pain syndrome: a review.  Ann Vasc Surg. 2008;  22 297-306
    Google Scholar
  • 13 Hsu ES. Practical management of complex regional pain syndrome.  Am J Ther. 2009;  16 147-154
    Google Scholar
  • 14 Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS).  Neurosci Lett. 2008;  437 199-202
    Google Scholar
  • 15 Benemei S, Nicoletti P, Capone JG. et al . CGRP receptors in the control of pain and inflammation.  Curr Opin Phamacol. 2009;  9 9-14
    Google Scholar
  • 16 Anand P, Whiteside G, Fowler CJ. et al . Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.  Brain Res Rev. 2009;  60 255-266
    Google Scholar
  • 17 Blaes F, Tschernatsch M, Braeu ME. et al . Autoimmunity in complex-regional pain syndrome.  Ann N Y Acad Sci. 2007;  1107 168-173
    Google Scholar
  • 18 Saab CY, Hains BC. Remote neuroimmune signalling: a long-range mechanism of nociceptive network plasticity.  TINS. 2009;  32 110-117
    Google Scholar
  • 19 Momin A, McNaughton PA. Regulation of firing frequency in nociceptive neurons by pro-inflammatory mediators.  Exp Brain Res. 2009;  196 45-52
    Google Scholar
  • 20 Gibbs GF, Drummond PD, Finch PM. et al . Unravelling the pathophysiology of complex regional pain syndrome: focus on sympathetically maintained pain.  Clin Exp Pharmacol Physiol. 2008;  35 717-724
    Google Scholar
  • 21 Zamponi GW, Lewis RJ, Todorovic SM. et al . Role of voltage-gated calcium channels in ascending pain pathways.  Brain Res Rev. 2009;  60 84-89
    Google Scholar
  • 22 Hans G, Schmidt BL, Strichartz G. Nociceptive sensitization by endothelin-1.  Brain Res Rev. 2009;  60 36-42
    Google Scholar
  • 23 Benarroch EE. Descending monoaminergic pain modulation. Bidirectional control and clinical revelance.  Neurology. 2008;  71 217-221
    Google Scholar
  • 24 Cervero F. Spinal cord hyperexcitability and its role in pain and hyperalgesia.  Exp Brain Res. 2009;  196 129-137
    Google Scholar
  • 25 Heinricher MM, Tavares I, Leith JL. et al . Descending control of nociception: specifity, recruitment and plasticity.  Brain Res Rev. 2009;  60 214-235
    Google Scholar
  • 26 Abbadie C, Bhangoo S, De Koninck Y. et al . Chemokines and pain mechanisms.  Brain Res Rev. 2009;  60 125-134
    Google Scholar
  • 27 Neugebauer V, Galhardo V, Maione S. et al . Forebrain pain mechanisms.  Brain Res Rev. 2009;  60 226-242
    Google Scholar
  • 28 Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes.  Pain. 1997;  73 123-139
    Google Scholar
  • 29 Forouzanfar T, Köke AJA, van Kleef M. et al . Treatment of complex regional pain syndrome type I.  Eur J Pain. 2002;  6 105-122
    Google Scholar
  • 30 Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains.  Curr Opin Neurol. 2009;  22 epub ahead of print Sept 9
    Google Scholar
  • 31 Appelboom T. Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions.  Bone. 2002;  30 (S 05) S84-S86
    Google Scholar
  • 32 Yanow J, Pappagallo M, Pillai L. Complex regional pain syndrome (CRPS/RSD) and neuropathic pain: role of intravenous biphosphonates as analgesics.  ScientificWorldJournal. 2008;  8 229-236
    Google Scholar
  • 33 Maihöfner C, Birklein F. Complex regional pain syndrome: new aspects on pathophysiology and treatment (Article in German).  Fortschr Neurol Psychiatr. 2007;  75 331-342
    Google Scholar
  • 34 Pal M, Angaru S, Kodimuthali A. et al . Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management.  Curr Pharm Des. 2009;  15 1008-1026
    Google Scholar
  • 35 Wallace MS, Ridgeway BM, Leung AY. et al . Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II.  Anesthesiology. 2000;  92 75-83
    Google Scholar
  • 36 Wörz R, Wörz E. Long-term treatment of chronic pain with tilidine-naloxone. An analysis of 50 patients with chronic pain conditions of non-malignant origin.  Fortschr Med. 1995;  113 388-392 (Article in German)
    Google Scholar
  • 37 Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of cahronic pain.  Pain Pract. 2009;  9 71-81
    Google Scholar
  • 38 Norrbrink C, Lundeberg T. Tramadol in neuropathic pain after spinal cord injury: a rndomized, double-blind, placebo-controlled trial.  Clin J Pain. 2009;  25 177-184
    Google Scholar
  • 39 Grond S, Sablotzki A. Clinical pharmacology of tramadol.  Clin Pharmacokinet. 2004;  43 879-923
    Google Scholar
  • 40 Sinis N, Birbaumer N, Gustin S. et al . Memantine treatment of complex regional pain syndrome: a preliminary report of six cases.  Clin J Pain. 2007;  23 237-243
    Google Scholar
  • 41 Moore RA, Straube S, wiffen PJ. et al . Pregabalin for acute and chronic pain in adults.  Cochrane Database of Systematic Reviews. 2009;  Issue 3 Art. No.: CD007076. DOI: 10.1002/14651858.CD007076.pub2.
    Google Scholar
  • 42 Mizoguchi H, Watanabe C, Yonezawa A. et al . New therapy for neuropathic pain.  Int Rev Neurobiol. 2009;  85 249-260
    Google Scholar
  • 43 Zin CS, Nissen LM, Smith MT. et al . An update on the pharmacological management of post-herpetic neuralgia and painful diabetic polyneuropathy.  CNS Drugs. 2008;  22 417-442
    Google Scholar
  • 44 Yalcin I, Choucair-Jaafar N, Benbouzid M. et al . β2-adrenoreceptors are critical for antidepressant treatment of neuropathic pain.  Ann Neurol. 2009;  65 218-225
    Google Scholar
  • 45 Dick IE, Brochu RM, Purohit Y. et al . Sodium channel blockade may contribute to the analgesic efficacy of antidepressants.  J Pain. 2007;  8 315-324
    Google Scholar
  • 46 Saarto Z, Wiffen SJ. Antidepressants for neuropathic pain.  Cochrane Database of Systematic Reviews. 2007;  (Issue 4.) Art.Nr.: CD005454.DOI: 10.1002/14651858.CD005454.pub2
    Google Scholar
  • 47 Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine.  Pharmacotherapy. 2004;  24 621-629
    Google Scholar
  • 48 Sultan A, Gaskell H, Derry S. et al . Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomized trials.
  • 49 Slonimski M, Abram SE, Zuniga RE. Intrathecal baclofen in pain management.  Reg Anesth Pain Med. 2004;  29 269-276
    Google Scholar
  • 50 Rauck RL, Eisenach JC, Jackson K. et al . Epidural clonidine treatment for refractory reflex sympathetic dystrophy.  Anesthesiology. 1993;  79 1163-1169
    Google Scholar
  • 51 Ranoux D, Attal N, Morain F. et al . Botulinum toxin A induces direct analgesic effects in chronic neuropathic pain.  Ann Neurol. 2008;  64 274-283
    Google Scholar
  • 52 Carroll I, Clark JD, Mackey S. Sympathetic block with botulinum toxin to treat complex regional pain syndrome.  Ann Neurol. 2009;  65 348-351
    Google Scholar
  • 53 Munts AG, van der Plas AA, Vormoolen JH. et al . Intrathecal glycine for pain and dystonia in complex regional pain syndrome.  Pain. 2009;  epub ahead of print August 13.
    Google Scholar
  • 54 Sheets PL, Heers C, Stoehr T. et al . Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine.  J Pharmacol Exp Ther. 2008;  326 89-99
    Google Scholar
  • 55 Daly AE, Bialocerkowski AE. Does evidence support physiotherapy management of adult complex regional pain syndrome type one?.  A systematic review. Eur J Pain. 2009;  13 339-353
    Google Scholar
  • 56 Bruehl S, Chung OY. Psychological and behavioural aspects of complex regional pain syndrome.  Clin J Pain. 2006;  22 430-437
    Google Scholar
  • 57 Kalita J, Vajpayee A, Misra UK. Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trial.  QJM. 2006;  99 89-95
    Google Scholar
  • 58 Perrigot M, Bergego C, Hocini A. et al . Algodystrophy sindrome in emiplegia. Clinical and therapeutic study (article in French).  Ann Med Interne. 1982;  133 544-548
    Google Scholar
  • 59 Gallien P, Nicolas B, Robineau S. et al . The reflex sympathetic dystrophy syndrome in patients who have had a spinal cord injury.  Paraplegia. 1995;  33 715-720
    Google Scholar
  • 60 Sullivan M. Integrated treatment of a women with chronic hand pain.  Hosp Comm Psychiatry. 1991;  42 474-475
    Google Scholar
  • 61 Harke H, Gretenkort P, Ladleif HU. et al . The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained release morphine in patients pretreated with spinal cord stimulation: a double-blind randomized study.  Anesth Analg. 2001;  92 488-495
    Google Scholar
  • 62 van de Vusse AC, Stomp-van den Berg SG, Kessels AH. et al . Randomised controlled trial of gabapentin in complex regio5nal pain syndrome type 1 (ISRCTN84121379).  BMC Neurol. 2004;  Sep 29; 4 13-1
    Google Scholar
  • 63 Serpell MG. Neuropathic pain study group . Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo controlled trial.  Pain. 2002;  99 557-566
    Google Scholar
  • 64 Sigtermans MJ, van Hilten JJ, Bauer MC. et al . Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1.  Pain. 2009;  145 304-311
    Google Scholar
  • 65 Sigtermans M, Noppers I, Sarton E. et al . An observational study on the effect of S(+)-ketamine on chronic pain versus experimental acute pain in complex regional pain syndrome type 1 patients.  Eur J Pain. 2009;  epub ahead of print June 17
    Google Scholar
  • 66 Kiefer RT, Rohr P, Ploppa Dietrich HJ. et al . Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study.  Pain Med. 2008;  9 1173-1201
    Google Scholar
  • 67 Correll GE, Maleki J, Gracely EJ. et al . Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome.  Pain Med. 2004;  5 263-275
    Google Scholar
  • 68 Goldberg ME, Domsky R, Scaringe D. et al . Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome.  Pain Physician. 2005;  8 175-179
    Google Scholar
  • 69 Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. Pain 2009: epub ahead August 22
  • 70 Kiefer RT, Rohr PA, Nohé B. et al . A pilot open-label study of the efficacy of subanesthetic isomeric S(+)-ketamine in refractory CRPS patients.  Pain Med. 2008;  9 44-54
    Google Scholar
  • 71 Sinis N, Birbaumer N, Schwarz A. et al . Memenatine und komplexes regionales Schmerzsyndrom (CRPS): Behandlungseffekte und kortikale Reorganisation.  Handchir Mikrochir Plast Chir. 2006;  38 164-171
    Google Scholar
  • 72 Eiche J, Krimmer H, Lanz U. et al . Treatment of hand surgery patients in chronic pain (Article in German)].  Orthopäde. 2003;  32 413-417
    Google Scholar
  • 73 Agrawal S, Polydefkis M, Block B. et al . Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states.  Pain Med. 2007;  8 554-562
    Google Scholar
  • 74 Simpson DM, Messina J, Xie F. et al . Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant adult patinets with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.  Clin Ther. 2007;  29 588-601
    Google Scholar
  • 75 Moulin DE, Palma D, Watling C. et al . Methadone in the management of intractable neuropathic noncancer pain.  Can J Neurol Sci. 2005;  32 340-343
    Google Scholar
  • 76 Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids.  Acta Chir Scand. 1982;  148 653-655
    Google Scholar
  • 77 Braus DF, Krauss JK, Strobel J. The shoulder-hand syndrome after stroke: prospective clinical trial.  Ann Neurol. 1994;  36 728-733
    Google Scholar
  • 78 Bianchi C, Rossi S, Turi S. et al . Long-term functional outcome measures in corticosteroid-treated complex regional pain syndrome.  Eura Medicophys. 2006;  42 103-111
    Google Scholar
  • 79 Inchiosa Jr MA, Kizelshteyn G. Treatment of complex regional pain syndrome type I with oral phenoxybenzamine: rationale and case reports.  Pain Pract. 2008;  8 125-132
    Google Scholar
  • 80 Gobelet C, Waldburger M, Meier JL. The effect of adding calcitonin to physical treatment on reflex sympathetic dystrophy.  Pain. 1992;  48 171-175
    Google Scholar
  • 81 Bickerstaff DR, Kanis JA. The use of nasal calcitonin in the treatment of posttraumatic algodystrophy.  Br J Rheumatol. 1991;  30 291-294
    Google Scholar
  • 82 Perez RS, Kwakkel G, Zuurmons WW. et al . Treatment of reflex sympathetic dystrophy (CRPS type I): a research synthesis of 21 randomized clinical trials.  J Pain Symptom Manage. 2001;  21 511-526
    Google Scholar
  • 83 Sahin F, Yilmaz F, Kotevoglu N. et al . Efficacy of salmon calcitonin in complex regional pain syndrome (type I) in addition to physical therapy.  Clin Rheumatol. 2006;  25 143-148
    Google Scholar
  • 84 Brunner F, Schmid A, Kissling R. et al . Biphosphonates for the therapy of complex regional pain syndrome I – systematic review.  Eur J Pain. 2009;  13 17-21
    Google Scholar
  • 85 Manicourt DH, Brasseur JP, Boutsen Y. et al . Role of elndronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity.  Arthritis Rheum. 2004;  50 3690-3697
    Google Scholar
  • 86 Adami S, Fossaluzza V, Gatti D. et al . Biphosphonate therapy of reflex sympathetic dystrophy sindrome.  Ann Rheum Dis. 1997;  56 201-204
    Google Scholar
  • 87 Varenna M, Zucchi F, Ghiringhelli D. et al . Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind placebo controlled study.  J Rheumatol. 2000;  27 1477-1483
    Google Scholar
  • 88 Breuer B, Pappagallo M, Ongseng F. et al . An open-lanbel pilot trial of ibandronate for complex regional pain syndrome.  Clin J Pain. 2008;  24 685-689
    Google Scholar
  • 89 Robinson JN, Sandom J, Chapman PT. Efficacy of pamidronate in complex regional pain syndrome type I.  Pain Med. 2004;  5 276-280
    Google Scholar
  • 90 Zuniga RE, Perera S, Abram SE. Intrathecal baclofen:a useful agent in the treatment of well-established complex regional pain syndrome.  Reg Anesth Pain Med. 2002;  27 90-93
    Google Scholar
  • 91 Van Rijn MA, Munts AG, Marinus J. et al . Intrathecal baclofen for dystonia of complex regional pain syndrome.  Pain. 2009;  143 41-47
    Google Scholar
  • 92 Van Hilten BJ, van de Beek WJ, Hoff JI. et al . Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy.  N Engl J Med. 2000;  343 625-630
    Google Scholar
  • 93 Perez RS, Zuurmond WW, Bezemer PD. et al . The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study.  Pain. 2003;  102 297-307
    Google Scholar
  • 94 Ribbers GM, Stam HJ. Complex regional pain syndrome type I treated with topical capsaicin: a case report.  Arch Phys Med Rehabil. 2001;  82 851-852
    Google Scholar
  • 95 Zuurmond WW, Langendijck PN, Bezemer PD. et al . Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream.  Acta Anaesthesiol Scand. 1996;  40 364-367
    Google Scholar
  • 96 Rajkumar SV, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment.  Arch Intern Med. 2001;  161 2502-2503
    Google Scholar
  • 97 Bernateck M, Rolke R, Birklein F. et al . Successful intravenous regional block with low-dose tumor necrosis factor-α antibody infliximab for treatment of complex regional pain syndrome 1.  Anesth Analg. 2007;  105 1148-1151
    Google Scholar
  • 98 French J, Gronseth G. Invited article: lost in a jungle of evidence – we need a compass.  Neurology. 2008;  71 1634-1638
    Google Scholar

Korrespondenzadresse

PD Stephan Rüegg

Universitätsspital Basel

Neurologie

Petersgraben 4

4031 Basel

Schweiz

eMail: srueegg@uhbs.ch